Torrent Pharmaceuticals is reportedly planning to increase its research and development (R&D) spend by over 50 per cent to about 7-8 per cent of its turnover. The company has close to ten launches in the coming fiscal year and most of them will take place before the end of calendar year 2016. Torrent is one of the few Indian pharma companies which has not been plagued by the US drug regulator and has been largely successful in meeting the compliance standards of the USFDA.
Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.
